Can passengers dictate the direction of the prognosis?

An editorial paper is published in oncology science A paper by Peter Kaliftalla, a researcher at the University of Helsinki and University Hospital Comprehensive Cancer Center, titled “Cancer mutation signatures: Can passengers set the direction of prognosis?”

In the early days of cancer genomics, the field was primarily focused on discovering driver mutations that drive cancer progression. After the rapid development of modern sequencing technology in the early 2010s, it became clear that passenger mutations are not just random, unrelated fragments, but may be scars generated during the fundamental biological process of tumor development. therefore, historical record of carcinogenic.

This paved the way for mutational signatures, a concept that is today defined as a characteristic pattern of somatic mutations that occur in cancer genomes.

Although there are multiple ways to characterize mutational signatures, COSMIC (Catalog of Somatic Mutations in Cancer) signatures have been extensively studied and represent the most comprehensive and clinically relevant collection of mutational signatures to date. It is recognized as one. For example, certain COSMIC single nucleotide substitution (SBS) mutational signatures may be due to defects in, or secondary to, specific DNA proofreading mechanisms (e.g., SBS10), exposure to specific chemotherapy (e.g., SBS17). There is a gender. smoking (Example: SBS4). Still, the association between mutational signature and prognosis remained unclear until recently.

“The two of us Recent paperUsing publicly available data from the Cancer Genome Atlas (TCGA) and Pan-Cancer Analysis of Whole Genomes (PCAWG) databases, we show that the presence of several COSMIC mutation signatures is associated with higher We also evaluated whether the prognostic value could be improved. It includes a total of 13 histological types of cancer, including gastrointestinal and urinary cancers,” says Kariftala.